In continuation to earlier letter dated July 16, 2022 with respect to the approval granted to Orchid-Bio Pharma (wholly owned subsidiary) by Competent Authority under the Production Linked Incentive (PLI) Scheme for manufacturing of product ‘7 ACA’, Orchid Pharma has informed that the Company and Orchid Bio Pharma has entered into a Memorandum of Understanding (MoU) with an overseas technology provider for in-licensing 7ACA technology.
The above information is a part of company’s filings submitted to BSE.
